Study of two oral chemo medicines for advanced bile duct cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two oral chemotherapy medicines (D07001 softgel plus Xeloda/TS-1) in people with advanced bile duct tract cancer that can’t be removed by surgery. It’s for situations where first-line gemcitabine plus cisplatin chemotherapy no longer worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older (or 20+ if you live in Taiwan).
- You have unresectable or metastatic bile tract cancer (cholangiocarcinoma, gallbladder cancer, or ampullary cancer).
- Your first chemotherapy (gemcitabine + cisplatin) didn’t work or you had to stop it.
- Your body is strong enough for treatment: ECOG performance status 0–1, and you have enough blood, liver, and kidney function.
- You have no major recent treatment overlap: no other chemotherapy since first-line, and the last chemo was within 60 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy, immunotherapy, and heat therapy (hyperthermia) with a special radiation technique for advanced bile duct or gallbladder cancer that hasn't been treated before. It aims to see if this combination can help shrink tumors and improve outcomes.
This trial tests a combination of anlotinib (a targeted therapy) and two chemotherapy drugs (nab-paclitaxel and S-1) for people with advanced bile duct cancer whose disease has worsened after first-line gemcitabine-based chemotherapy. The goal is to see if this combination can help shrink or control the tumor.
This trial tests a combination of two chemotherapy drugs (trifluridine/tipiracil and oxaliplatin) for people with advanced or metastatic bile duct cancer (including gallbladder cancer) who have only had one prior treatment. The goal is to see if this combination can help control the cancer.
This study tests a new drug called BL-B01D1 against standard treatment options for patients with advanced biliary tract cancer (cancer of the bile ducts) that has stopped responding to platinum chemotherapy and immunotherapy. The drug is designed to target and destroy cancer cells more effectively.
This Phase 2 trial tests a combination of three medicines (GEMOX, donafenib, and tislelizumab) for advanced bile duct cancer. It aims to see if the treatment can shrink tumors and improve outcomes in people with certain tumor stage and health test results.
This trial tests a combination of two oral medications, D07001 and capecitabine, for people with advanced bile duct, gallbladder, or ampullary cancer that has gotten worse after standard chemotherapy. The goal is to see if this combination can help control the cancer.
Hear when a new Biliary Tract Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.